Chapter 31 : The BCG Experience: Implications for Future Vaccines against Tuberculosis

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

The BCG Experience: Implications for Future Vaccines against Tuberculosis, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818357/9781555819101_Chap31-1.gif /docserver/preview/fulltext/10.1128/9781555818357/9781555819101_Chap31-2.gif


Use of BCG (bacille Calmette-Guérin) vaccines increased in Europe after World War II and in developing countries starting in the 1950s to the extent that the vaccines have now been given to over 3 billion people. In a major evaluation of BCG's safety, researchers attempted to catalog all adverse events reported as attributed to BCG vaccination. Two conclusions are notable. First, the reports of severe neurologic or fatal sequelae indicate that the risk of such events is extremely rare, far less than that reported for the smallpox vaccine. Second, BCG vaccines are associated with a variety of more common minor adverse effects in addition to induration and ulceration of the vaccination site, which occur in almost all vaccines. The authors believe that such studies may identify useful surrogate markers for the evaluation of different preparations of BCG or new vaccines against tuberculosis. Although BCG is effective in developing type I CD4 T-cell responses, it is still unclear how effective it is in generating MHC class I-restricted CTL responses. It may ultimately be necessary to identify the molecules, either enzymes or lysins, that enable to escape from phagolysosomes into the cytoplasm in order to develop recombinant BCG vaccines that are effective in inducing both CD8- and CD4-type protective responses. Just as the BCG trials have provided our most detailed studies of the epidemiology of tuberculosis, so basic research directed at tuberculosis vaccines is leading the way in understanding pathogenesis of the disease.

Citation: Bloom B, Fine P. 1994. The BCG Experience: Implications for Future Vaccines against Tuberculosis, p 531-557. In Bloom B (ed), Tuberculosis. ASM Press, Washington, DC. doi: 10.1128/9781555818357.ch31
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of Figure 1
Figure 1

Estimation of protective efficacy of BCG vaccination against tuberculosis derived from case-control studies, contact studies, and comparisons between vaccination rate among patients and the general population. Vaccine efficacy is shown on a logarithmic scale, and the bars indicate 95% confidence intervals. ( )

Citation: Bloom B, Fine P. 1994. The BCG Experience: Implications for Future Vaccines against Tuberculosis, p 531-557. In Bloom B (ed), Tuberculosis. ASM Press, Washington, DC. doi: 10.1128/9781555818357.ch31
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Anacker, R. L.,, W. R. Barclay,, W. Brehwer,, G. Goude,, R. H. List,, E. Ribi,, and D. F. Tarmina. 1969. Effectiveness of cell walls of Mycobacterium bovis strain BCG administered by various routes and in different adjuvants in protecting mice against airborne infection with Mycobacterium tuberculosis strain H37Rv. Am. Rev. Respir. Dis. 99:242248.
2. Anacker, R. L.,, W. Brehmer,, W. R. Barclay,, W. R. Leif,, E. Ribi,, J. H. Simmons,, and A. W. Smith. 1972. Superiority of intravenous BCG and BCG cell walls in protecting rhesus monkeys (Macaca mulatto) against airborne tuberculosis. Z. Immunitaetsforsch. 143:363.
3. Andersen, P. Vaccination of mice against M. tuberculosis infection: protective immunity obtained with a soluble mixture of secreted mycobacterial proteins. Submitted for publication.
4. Aronson, J. D.,, C. F. Aronson,, and H. C. Taylon. 1958. A twenty-year appraisal of BCG vaccination in the control of tuberculosis. Arch. Intern. Med. 101:881893.
5. Barclay, W. R.,, W. M. Busey,, D. W. Dalgard,, R. C. Good,, B. W. Janicki,, J. E. Kasik,, E. Ribi,, C. E. Ulrich,, and E. Wolinsky. 1973. Protection of monkeys against airborne tuberculosis by aerosol vaccination with Bacillus Calmette-Guerin. Am. Rev. Respir. Dis. 107:351358.
6. Bjartveit, K.,, and H. Waaler. 1965. Some evidence of the efficacy of mass BCG vaccination. Bull. W.H.O. 33:289319.
7. Bloom, B. R.,, R. L. Modlin,, and P. Salgame. 1992. Stigma variations: observations on suppressor T cells and leprosy. Annu. Rev. Immunol. 10:453488.
8. Bloom, B. R.,, and C. J. L. Murray. 1992. Tuberculosis: commentary on a reemergent killer. Science 257:10551064.
9. Braun, M. M.,, and G. Cauthen. 1992. Relationship of the human immunodeficiency virus epidemic to pediatric tuberculosis and Bacillus Calmette-Guerin immunization. Pediatr. Infect. Dis. J. 11:220227.
10. Bretcher, P. A. 1992a. A strategy to improve the efficacy of vaccination against tuberculosis and leprosy. Immunol. Today 13:342345.
11. Bretcher, P. A. 1992b. Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science 260:539542.
12. British Thoracic Association. 1980. Effectiveness of BCG vaccination in Great Britain in 1978. Br. J. Chest Dis. 74:215227.
13. Brown, C. A.,, I. N. Brown,, and S. Swinburne. 1985. The effect of oral Mycobacterium vaccae on subsequent responses to BCG sensitization. Tubercle 66:251260.
14. Calmette, A. 1927. La Vaccination Preventive contra la Tuberculosis, 250 p. Masson et Cie, Paris.
15. Calmette, A.,, B. Weill-Halle,, A. Saenz,, and L. Costil. 1933. Demonstration experimentale du passage des bacilles vaccines BCG a travers la muquese intestinale chez l'infant et chez le singe. Bull. Acad. Med. 110:203206.
16. Canetti, G. 1955. The Tubercle Bacillus in the Pulmonary Lesion of Man, 226 p. Springer, New York.
17. Centers for Disease Control. 1991. BCG vaccination and pediatric HIV infection—Rwanda, 1988-90. Morbid. Mortal. Weekly Rep. 40:833835.
18. Chamberlayne, E. C. (ed.). 1972. Status of Immunization in Tuberculosis in 1971, 249 p. Department of Health, Education and Welfare, Washington, D.C.
19. Chan, J.,, Y. Xing,, R. S. Magliozzo,, and B. R. Bloom. 1992. Killing of virulent M. tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J. Exp. Med. 175:11111122.
20. Cheng, S. H.,, K. B. Walker,, D. B. Lowrie,, D. A. Mitchison,, R. Swamy,, M. Datta,, and R. Prabhaka. 1993. Monocyte antimycobacterial activity before and after Mycobacterium bovis BCG vaccination in Chingleput, India, and London, United Kingdom. Infect. Immun. 61:45014503.
21. Clemens, J. D.,, J. H. Jackie,, J. H. Chuong,, and A. R. Feinstein. 1983. The BCG controversy: a methodological and statistical reappraisal. JAMA 249:23622369.
22. Coetzee, A. M.,, and J. Berjak. 1968. BCG in the prevention of tuberculosis in an adult population. Proc. Mine Med. Officers Assoc. 48:4153.
23. Cohn, M. L.,, C. L. Davis,, and G. Middlebrook. 1958. Airborne immunization against tuberculosis. Science 128:12821283.
24. Colditz, G. A.,, T. Brewer,, C. Berkey,, M. Wilson,, E. Burdick,, H. V. Fineberg,, and F. Mosteller. The efficacy of BCG in the prevention of tuberculosis: meta-analyses of the published literature. JAMA, in press.
25. Comstock, G. W. 1978. Tuberculosis in twins: a re-analysis of the Prophit survey. Am. Rev. Respir. Dis. 117:621624.
26. Comstock, G. W. 1988. Identification of an effective vaccine against tuberculosis. Am. Rev. Respir. Dis. 138:479480.
27. Comstock, G. W.,, V. T. Livesay,, and S. F. Woolpert. 1974. Evaluation of BCG vaccination among Puerto Rican Children. Am. J. Public Health 64:283291.
28. Comstock, G. W.,, and C. E. Palmer. 1966. Long-term results of BCG vaccination in the southern United States. Am. Rev. Respir. Dis. 93:171183.
29. Comstock, G. W.,, and R. G. Webster. 1969. Tuberculosis studies in Muscogee County, Georgia. VII. A twenty-year evaluation of BCG vaccination in a school population. Am. Rev. Respir. Dis. 100:839845.
30. Comstock, G. W.,, S. F. Woolpert,, and V. T. Livesay. 1976. Tuberculosis studies in Muscogee County, Georgia. Twenty-year evaluation of a community trial of BCG vaccination. Public Health Rep. 91: 276280.
31. Convit, J.,, N. Aranzazu,, M. Ulrich,, M. E. Pinardi,, O. Reyes,, and J. Alvarado. 1982. Immunotherapy with a mixture of Mycobacterium leprae and BCG in different forms of leprosy and Mitsuda negative contacts. Int. J. Lepr. 50:415.
32. Cooper, A. M.,, D. K. Dal ton,, T. A. Stewart,, D. G. Griffin,, D. G. Ressell,, and I. M. Orme. 1993. Disseminated tuberculosis in IFN-γ gene-disrupted mice. J. Exp. Med. 178:22422248.
33. Dahlstrom, G.,, and H. Difs. 1951. The efficacy of BCG vaccination: a study on vaccinated and tuberculin-negative conscripts. Acta Tuberc. Scand. Suppl. 27:1.
34. Das, S.,, S. L. Chan,, B. W. Allan,, D. A. Mitchison,, and D. B. Lowrie. 1993. Application of DNA fingerprinting with IS986 to sequential mycobacterial isolates from pulmonary tuberculosis patients in Hong Kong before, during and after short-course chemotherapy. Tuberc. Lung Dis. 74:4751.
35. Edwards, L. B.,, F. A. Acquaviva,, and V. T. Livesay. 1973. Identification of tuberculous infected. Dual tests and density of reaction. Am. Rev. Respir. Dis. 108:13341339.
36. Edwards, L. B.,, F. A. Acquaviva,, V. T. Livesay,, F. W. Cross,, and C. E. Palmer. 1969. An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am. Rev. Respir. Dis. 99:1132.
37. Edwards, L. B.,, and C. E. Palmer. 1958. Epidemiologic studies of tuberculin sensitivity. I. Preliminary results from purified protein derivatives prepared from atypical acid-fast organisms. Am. J. Hyg. 68:213231.
38. Etemadi, A.,, R. Farid,, and J. L. Stanford. 1992. Immunotherapy for drug resistant tuberculosis. Lancet 340:13601361. (Letter.)
39. Fenner, F.,, D. A. Henderson,, I. Arita,, Z. Jezek,, and I. D. Ladnyi. 1988. Smallpox and Its Eradication, 1,460 p. World Health Organization, Geneva.
40. Ferguson, R. G.,, and A. B. Simes. 1949. BCG vaccination of Indian infants in Saskatchewan. Tubercle 30:511.
41. Fine, P. E. M. 1981. Immunogenetics of susceptibility to leprosy, tuberculosis and leishmnaniasis: an epidemiological perspective. Int. J. Lepr. 49:337454.
42. Fine, P. E. M. 1984. Leprosy and tuberculosis—an epidemiological comparison. Tubercle 65:137153.
43. Fine, P. E. M. 1988. BCG vaccination against tuberculosis and leprosy. Br. Med. Bull. 44:691703.
44. Fine, P. E. M. 1989. The BCG story: lessons from the past and implications for the future. Rev. Infect. Dis. 11(Suppl. 2):S353S359.
45. Fine, P. E. M.,, and J. M. Ponnighaus. 1988. Background, design and prospects of the Karonga Prevention Trial, a leprosy vaccine trial in Northern Malawi. Trans. R. Soc. Trop. Med. Hyg. 82:810817.
46. Fine, P. E. M.,, and L. C. Rodrigues. 1990. Modern vaccines: mycobacterial diseases. Lancet 335:10161020.
47. Fine, P. E. M.,, J. A. C. Sterne,, J. M. Ponnighaus,, and R. J. W. Rees. Delayed-type hypersensitivity, mycobacterial vaccines and protective immunity. Submitted for publication.
48. Flynn, J. L.,, D. Mathis,, C. Benoist,, T. Mak,, and B. R. Bloom. Unpublished data.
49. Flynn, J. L.,, J. Chan,, K. J. Triebold,, D. K. Dalton,, T. A. Stewart,, and B. R. Bloom. 1993. An essential role for interferon-γ in resistance to M. tuberculosis. J. Exp. Med. 178:22492254.
50. Flynn, J. L.,, M. Goldstein,, K. J. Triebold,, B. Koller,, and B. R. Bloom. 1992. MHC class I restricted T cells are required for resistance to M. tuberculosis infection. Proc. Natl. Acad. Sci. USA 89:1201312017.
51. Fok, J. S.,, R. S. Ho,, P. K. Arora,, G. E. Harding,, and D. W. Smith. 1976. Host-parasite relationships in experimental airborne tuberculosis. V. Lack of hematogenous dissemination of Mycobacterium tuberculosis to the lungs in animals vaccinated with Bacille Calmette-Guerin. J. Infect. Dis. 133:137144.
52. Frappier, A.,, V. Portelance,, J. St -Pierre,., and M. Panisset,. 1972. BCG strains: characteristics and relative efficacy, p. 157178. In E. C. Chamberlayne (ed.), Status of Immunization in Tuberculosis in 1971. Department of Health, Education and Welfare publication no. (NIH) 72-68. Government Printing Office, Washington, D.C.
53. Frimodt-Moller, J.,, G. S. Acharyulu,, and K. Kesava Pillai. 1973. Observations on the protective effect of BCG vaccination in a South Indian rural population: fourth report. Bull. Int. Union Tuberc. 48:4052.
54. Fujimura, Y. 1986. Functional morphology of microfold cells (M cells) in Peyer's patches—phagocytosis and transport of BCG by M cells into rabbit Peyer's patches. Gastroenterol. Jpn. 21:325335.
55. Ganjam, K.,, B. R. Bloom,, and W. R. Jacobs, Jr. 1991. Insertional mutagenesis and illegitimate recombination in mycobacteria. Proc. Natl. Acad. Sci. USA 88:54335437.
56. Gaudier, B.,, and C. Gernez-Rieux. 1962. Etude experimentale de la vitality du B.C.G. au cours de la traversee gastro-intestinale chez des enfants non allergiques vaccinas par voie digestive. Ann. Inst. Pasteur (Lille) 13:7787.
57. Geiseler, R. J.,, K. E. Nelsen,, R. G. Crispen,, and V. K. Moses. 1986. Tuberculosis in physicians: a continuing problem. Am. Rev. Respir. Dis. 133:773778.
58. Good, R. C. 1968. Biology of the mycobacterioses. Simian tuberculosis: immunologic aspects. Ann. N.Y. Acad. Sci. 154:200213.
59. Greenberg, P. D.,, K. G. Lax,, and C. B. Schechter. 1991. A decision analysis comparing the tuberculin screening strategy with the BCG vaccination. Am. Rev. Respir. Dis. 143:489495.
60. Greenwood, M. 1928. Professor Calmette's statistical study of BCG vaccination. Br. Med. J. 1:793795.
61. Grzybowski, S. 1980. Epidemiology of tuberculosis and the role of BCG. Clin. Chest Med. 1:175187.
62. Guérin, C., 1957. The history of BCG, p. 4853. In S. R. Rosenthal (ed.), BCG Vaccination against Tuberculosis. Little, Brown & Co., Boston.
63. Hank, J. A.,, J. K. Chan,, M. L. Edwards,, D. Muller,, and D. W. Smith. 1981. Influence of the virulence of Mycobacterium tuberculosis on protection induced by Bacille Calmette-Guerin in guinea pigs. J. Infect. Dis. 143:734738.
64. Hart, P. D. 1967. Efficacy and applicability of massBCG vaccination in tuberculosis control. Br. Med. J. 1:587592.
65. Hart, P. D.,, and I. Sutherland. 1977. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br. Med. J. 22:293295.
66. Hart, P. D.,, I. Sutherland,, and J. Thomas. 1967. The immunity conferred by effective BCG and vole bacillus vaccines, in relation to the induced tuberculin sensitivity and to technical variations in the vaccines. Tubercle 48:201210.
67. Kaufmann, S. H. E. 1988. CD8+ T lymphocytes in intracellular microbial infections. Immunol. Today 9:168174.
68. Kaufmann, S. H. E. 1993. Immunity to intracellular bacteria. Annu. Rev. Immunol. 11:129163.
69. King, C. H.,, S. Mundayoor,, J. T. Crawford,, and T. M. Shinnick. 1993. Expression of contact-dependent cytolytic activity by M. tuberculosis and isolation of the genomic locus that encodes the activity. Infect. Immun. 61:27082712.
70. Kirschner, R. A., Jr.,, B. C. Parker,, and J. O. FalkinhamIII . 1992. Epidemiology of infection by nontu-berculous mycobacteria. Am. Rev. Respir. Dis. 145: 272275.
71. Lallemant-Le Coeur, S.,, M. Lallemant,, D. Cheynier,, S. Nzingoula,, J. Drucker,, and B. Larouze. 1991. BCG immunization in infants born to HIV-1 seropositive mothers. AIDS 5:195199.
72. Langermann, S.,, S. Palaszynski,, A. Sadziene,, C. K. Stover,, and S. Koenig. Induction of sustained systemic and mucosal immunity by a single intranasal immunization with recombinant BCG. Submitted for publication.
73. Legranderie, M.,, P. Ravisse,, G. Marchal,, M. Gheorghiu,, V. Balasubramanian,, E. H. Weigeshaus,, and D. W. Smith. 1993. BCG induced protection in guinea pigs vaccinated and challenged via the respiratory route. Tuberc. Lung Dis. 74:3846.
74. Lex, A.,, K. H. Wiesmuller,, G. Jung,, and W. G. Bessler. 1986. A synthetic analogue of Escherichia coli lipoprotein, tripalmitoylpentapeptide, constitutes a potent immune adjuvant. J. Immunol. 137: 26672681.
75. Lotte, A.,, H. G. ten Dam,, and R. Henderson. 1988. Second IUATLK study on complications induced by intradermal BCG-vaccination. Bull. Int. Union Tuberc. 63:4783.
76. Lotte, A.,, O. Wasz-Hockert,, N. Poisson,, N. Domitrescu,, M. Verron,, and E. Covet. 1984. BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. Adv. Tuberc. Res. 21:107193.
77. Lubeck. 1935. Die Sauglingstuberkulose in Lubeck. Springer, Berlin.
78. Lurie, M. B. 1964. ResisTuberculosis. Experimental Studies in Native and Acquired Defense, 391 p. Harvard University Press, Cambridge, Mass..
79. Mackaness, G. B.,, D. J. Auclair,, and P. H. Lagrange. 1973. Immunopotentiation with BCG. I. Immune response to different strains and preparations. J. Natl. Cancer Inst. 51:16551667.
80. McAdam, R. A.,, T. Weisbrod,, J. D. Cirillo,, and W. R. Jacobs, Jr. Genetic analysis of IS1096: a study of transposition in M. bovis-BCG. Mol. Microbiol., in press.
81. McDonough, K. A.,, Y. Kress,, and B. R. Bloom. 1993. Pathogenesis of tuberculosis: interaction of Mycobacterium tuberculosis with macrophages. Infect. Immun. 61:27632773.
82. Medical Research Council. 1972. BCG and vole bacillus in the prevention of tuberculosis in adolescence and early adult life. Bull. W.H.O. 46:371385.
83. Middlebrook, G. 1961. Immunological aspects of airborne infection: reactions to inhaled antigens. Bacteriol. Rev. 25:331346.
84. Milstien, J. B.,, and J. J. Gibson. 1989. Quality Control of BCG Vaccines by the World Health Organization: a Review of Factors That May Influence Vaccine Effectiveness and Safety, 30 p. Publication WHO/EPI/Gen/89.1. World Health Organization, Geneva.
85. Mitchison, D. A. 1964. The virulence of tubercle bacilli from patients with pulmonary tuberculosis in India and other countries. Bull. Int. Union Tuberc. 35: 287293.
86. Momotoni, E.,, D. L. Whipple,, A. B. Thiermann,, and N. F. Cheville. 1988. Role of M cells and macrophages in the entrance of Mycobacterium paratuberculosis into domes of ileal Peyer's patches in calves. Vet. Pathol. 25:131137.
87. Murray, C. J. L.,, K. Styblo,, and A. Rouillon. 1990. Tuberculosis in developing countries: burden, intervention, and cost. Bull. Int. Union Tuberc. 65:624.
88. Narain, R.,, S. S. Nair,, G. Ramanatha Rao,, and P. Chandrasekhar. 1966. Distribution of tuberculous infection and disease among households in a rural community. Bull. W.H.O. 34:639654.
89. Onyebujoh, P.,, and G. A. W. Rook. 1991. Mycobacterium vaccae immunotherapy. Lancet 338:1534.
90. Orme, I. M.,, and F. M. Collins. 1984. Adoptive protection of the Mycobacterium tuberculosis infected lung: dissociation between cells that passively transfer protective immunity and those that transfer delayed-type hypersensitivity to tuberculin. Cell. Immun. 84:113120.
91. Osborn, T. W. 1983. Changes in BCG strains. Tubercle 64:1132.
92. Packe, G. E.,, and J. A. Innes. 1988. Protective effect of BCG in infant Asians: a case-control study. Arch. Dis. Child. 63:277281.
93. Padungchan, S.,, S. Konjanart,, S. Kasiratta,, S. Karamas,, and H. G. ten Dam. 1986. The effectiveness of BCG vaccination of the newborn against childhood tuberculosis in Bangkok. Bull. W.H.O. 64:247258.
94. Palmer, C. E. 1957. Contribution to Symposium on Value of Tuberculin Reactions for the Selection of Cases for BCG Vaccination and Significance of Post-Vaccination Allergy. Bull. Int. Union Tuberc. 27:106111.
95. Palmer, C. E.,, and M. W. Long. 1966. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am. Rev. Respir. Dis. 94:553568.
96. Parronchi, P.,, D. Macchia,, M. Piccinni,, P. Biswas,, C. Simonelli,, E. Maggi,, M. Ricci,, A. Asari,, and S. Romagnani. 1991. Allergen and bacterial antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production. Proc. Natl. Acad. Sci. USA 88:4538.
97. Ponnighaus, J. M.,, P. E. M. Fine,, J. A. C. Sterne,, R. S. Wilson,, E. Msosa,, P. J. K. Gruer,, P. A. Jenkins,, S. B. Lucas,, G. Liomba,, and L. Bliss. 1992. Efficacy of BCG against leprosy and tuberculosis in northern Malawi. Lancet 339:636639.
98. Rich, A. R. 1951. The Pathogenesis of Tuberculosis, 2nd ed, 1,028 p. Charles C Thomas, Publisher, Springfield, III.
99. Rodrigues, L. C., , V. K. Diwan,, and J. G. Wheeler. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int. J. Epidemiol., in press.
100. Rodrigues, L. .,, N. Gill,, and P. G. Smith. 1991. BCG vaccination in the first year of life protects children of Indian subcontinent ethnic origin against tuberculosis in England. J. Epidemiol. Community Health 45:7880.
101. Rodrigues, L. C.,, and P. G. Smith. 1990. Tuberculosis in developing countries and methods for its control. Trans. R. Soc. Trop. Med. Hyg. 84:739744.
102. Rosenthal, S. R. 1980. BCG Vaccine: Tuberculosis-Cancer, 404 p. PSG Publishing, Littleton, Mass.
103. Rosenthal, S. R.,, E. Loewinsohn,, M. L. Graham,, D. Liveright,, M. G. Thorne,, and V. Johnson. 1961. BCG vaccination against tuberculosis in Chicago: a twenty-year study statistically analyzed. Pediatrics 28:622641.
104. Rosenthal, S. R.,, J. T. McNery,, and N. Raisys. 1968. Aerogenic BCG vaccination against tuberculosis in animal and human subjects. J. Asthma Res. 5:309323.
105. Salgame, P.,, J. Abrams,, C. Clayberger,, H. Goldstein,, J. Convit,, R. L. Modlin,, and B. R. Bloom. 1991. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T-cell clones. Science 254:279282.
106. Schurr, E.,, D. Malo,, D. Radzloch,, E. Buschman,, K. Morgan,, P. Gros,, and E. Skamene. 1991. Genetic control of innate resistance to mycobacterial infections. Immunol. Today 12:4245.
107. Silva, C. L.,, and D. B. Lowrie. A single mycobacterial protein (hsp60) expressed by a transgenic antigen-presenting cell vaccinates mice against tuberculosis. Immunology, in press.
108. Singh, I. G.,, R. Mukherjee,, and G. P. Talwar. 1991. Resistance to intravenous inoculation of Mycobacterium tuberculosis H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on Mycobacterium W. Vaccine 9:1014.
109. Smith, D. W.,, E. H. Wiegeshaus,, R. N. Stark,, and G.-E. Harding,. 1972. Models for potency assay of tuberculosis vaccines, p. 205218. In E. C. Cham-berlayne (ed.), Status of Immunization in Tuberculosis in 1971. Department of Health, Education and Welfare, Washington, D.C.
110. Smith, P. G. 1982. Assessment of the efficacy of BCG vaccination against tuberculosis, using the case control method. Tubercle 62:2335.
111. Smith, P. G. 1988. Epidemiological methods to evaluate vaccine efficacy. Br. Med. Bull. 44:679690.
112. Smith, P. G. BCG vaccination. In P. D. O. Davies (ed.), Tuberculosis, in press. Chapman & Hall, Ltd., London.
113. Stead, W. W. 1992. Genetics and resistance to tuberculosis. Could resistance be enhanced by genetic engineering. Ann. Intern. Med. 116:937941.
114. Stead, W. W.,, J. P. Lofgren,, J. W. Senner,, and W. T. Reddick. 1990. Racial differences in susceptibility to infection with M. tuberculosis. N. Engl. J. Med. 322:422127.
115. Stover, C. K.,, V. F. de la Cruz,, T. R. Fuerst,, J. E. Burlein,, L. A. Benson,, L. T. Bennett,, G. P. Bansal,, J. F. Young,, M. H. Lee,, G. F. Hatfull,, S. B. Snapper,, R. G. Barletta,, W. R. Jacobs, Jr.,, and B. R. Bloom. 1991. New use of BCG for recombinant vaccines. Nature (London) 351:456460.
116. Styblo, K. 1991. Epidemiology of tuberculosis. Selected Papers R. Netherland Tuberc. Assoc. 24:1136.
117. Styblo, K.,, and J. Meyer. 1976. Impact of BCG vaccination programmes in children and young adults on the tuberculosis problem. Tubercle 57:1743.
118. Sutherland, I. 1981. The epidemiology of tuberculosis—is prevention better than cure. Bull. Int. Union Tuberc. 56:127134.
119. Sutherland, I.,, and I. Lindgren. 1979. The protective effect of BCG vaccination as indicated by autopsy studies. Tubercle 60:225231.
120. Sutherland, I.,, and V. H. Springett. 1987. Effectiveness of BCG vaccination in England and Wales in 1983. Tubercle 68:8192.
121. Tang, D. .,, M. DeVit,, and S. A. Johnston. 1992. Genetic immunization is a simple method for eliciting an immune response. Nature (London) 356:152154.
122. ten Dam, H. G. 1984. Research on BCG vaccination. Adv. Tuberc. Res. 21:79106.
123. ten Dam, H. G., 1993. BCG vaccination, p. 251269. In L. B. Reichman, and E. S. Hershfield (ed.), Tuberculosis. Marcel Dekker, New York.
124. ten Dam, H. G.,, and A. Pio. 1988. Pathogenesis of tuberculosis and effectiveness of BCG vaccination. Tubercle 63:226233.
125. ten Dam, H. G.,, K. I. Toman,, K. L. Hitze,, and J. Guld. 1976. Present knowledge of immunization against tuberculosis. Bull. W.H.O. 54:255269.
126. Tidjani, O.,, A. Amedome,, and H. G. ten Dam. 1986. The protective effect of BCG vaccination of the newborn against childhood tuberculosis in an African community. Tubercle 67:269281.
127. Tuberculosis Prevention Trial, Madras. 1980. Trial of BCG vaccines in South India for tuberculosis prevention. Indian J. Med. Res. 72(Suppl.):l74.
128. Vandiviere, H. M.,, M. Dworski,, I. G. Melvin,, K. A. Watsonk,, and J. Begley. 1973. Efficacy of Bacillus Calmette-Guerin and isoniazid-resistant Bacillus Calmette-Guerin with and without isoniazid chemoprophylaxis from day of vaccination. II. Field trial in man. Am. Rev. Respir. Dis. 108:301313.
129. Vidal, S. M.,, D. Malo,, K. Vogan,, E. Skamene,, and P. Gros. 1993. Natural resistance to infection with intracellular parasites: isolation of a candidate for BCG. Cell 73:469485.
130. Von Reyn, C. F., et al. 1987. Human immunodeficiency virus infection and routine childhood immunization. Lancet ii:669672.
131. Wang, B.,, K. E. Ugen,, V. Srikantan,, M. G. Agadjanyan,, K. Rang,, Y. Refaeli,, A. I. Sato,, J. Boyer,, W. V. Williams,, and D. B. Weiner. 1993. Gene inoculation generates immune responses against human immunodeficiency virus 1. Proc. Natl. Acad. Sci. USA 90:41564160.
132. Weigeshaus, E. H.,, and B. W. Smith. 1989. Review of the protective potency of new tuberculosis vaccines. Rev. Infect. Dis. ll(Suppl. 2):484490.
133. Weill-Halle, B., 1980. Routes and methods of administration: oral vaccination, p. 175181. In S. R. Rosenthal (ed.), BCG Vaccine: Tuberculosis-Cancer. PSG Publishing, Littleton, Mass.
134. Weltman, A. C, and D. N. Rose. 1993. The safety of Bacille Calmette-Guerin vaccination in HIV infection and AIDS. AIDS 7:149157.
135. Woods, G. L.,, and J. A. Washington II. 1987. Mycobacteria other than Mycobacterium tuberculosis: review of microbiologic and clinical aspects. Rev. Infect. Dis. 9:275294.
136. World Health Organization. 1966. Expert Committee on Biological Standardization. Technical report series no. 329. World Health Organization, Geneva.
137. World Health Organization. 1987. Expanded program on immunization: joint WHO/UNICEF statement on immunization and AIDS. Weekly Epidemiol. Ret: 62:5354.
138. World Health Organization. 1992. Expanded Program for Immunization. Program Report. World Health Organization, Geneva.
139. Youmans, G. P. 1979. Relationship between delayed-type hypersensitivity and immunity in tuberculosis, p. 302-316. In G. P. Youmans (ed.), Tuberculosis. The W. B. Saunders Co., Philadelphia. 62:5354.


Generic image for table
Table 1

Summary of major randomized BCG trials

Citation: Bloom B, Fine P. 1994. The BCG Experience: Implications for Future Vaccines against Tuberculosis, p 531-557. In Bloom B (ed), Tuberculosis. ASM Press, Washington, DC. doi: 10.1128/9781555818357.ch31

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error